8-K: Kalaris Therapeutics Appoints Matthew Gall as New CFO

Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall, a seasoned biopharmaceutical finance executive, as its new Chief Financial Officer and Treasurer, effective November 3, 2025.

Summary

• Kalaris Therapeutics, Inc. appointed Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025.
• Mr. Gall will also serve as the company's principal financial officer.
• He previously served as CFO of iTeos Therapeutics, Inc. from June 2020 to August 2025 and held various senior roles at Sarepta Therapeutics, Inc. from January 2013 to June 2020.
• His compensation package includes an annualized base salary of $485,000 and eligibility for an annual incentive bonus of up to 40% of his base salary.
• He was granted an incentive stock option to purchase 235,000 shares of common stock, with an exercise price equal to the closing price on The Nasdaq Global Market on the effective date, vesting over four years.
• The employment agreement includes severance provisions, with enhanced benefits in the event of a change in control.
• Brett Hagan ceased to serve as the company's principal financial officer but continues as Senior Vice President, Finance and Chief Accounting Officer.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced CFO is a positive step for strengthening financial leadership and strategic capabilities. While the compensation package is substantial, it is competitive for attracting top talent in the biopharmaceutical industry. The overall sentiment is positive due to the quality of the hire, tempered by the associated costs.

Positives

• Appointment of Matthew Gall, an experienced financial executive with a strong background in clinical-stage and commercial-stage biopharmaceutical companies (iTeos Therapeutics, Sarepta Therapeutics).
• His experience in corporate development and business development suggests a strategic financial perspective that could benefit the company's growth initiatives.
• The comprehensive compensation package, including significant equity, is designed to attract and retain high-caliber talent in a competitive industry.

Negatives

• The executive compensation package, including a $485,000 base salary, 40% target bonus, and 235,000 stock options, represents a substantial fixed and variable cost for the company.
• Generous severance provisions, particularly the change-in-control benefits (12 months salary, 100% target bonus, full equity acceleration), could be viewed as a 'golden parachute' and a significant liability in certain scenarios.

Risks

• Key Personnel Risk: The company's success is highly dependent on the continued service and performance of key executives like the new CFO.
• Executive Compensation Costs: The substantial compensation package could strain financial resources, especially for a clinical-stage company.
• Change in Control Liabilities: The enhanced severance package in a change-in-control scenario could increase acquisition costs or reduce shareholder value in such an event.
• Integration Risk: Potential challenges in integrating a new senior executive into the existing management team and corporate culture.

Future Outlook

The appointment of a new Chief Financial Officer with extensive experience in the biopharmaceutical sector suggests a focus on strengthening financial leadership and strategic development. The company aims to leverage Mr. Gall's expertise in corporate and business development to support its future growth and financial management.

Management Comments

• The Board of Directors appointed Matthew Gall as Chief Financial Officer and Treasurer of the Company, effective as of November 3, 2025.
• Mr. Gall will serve as the Company's principal financial officer.
• Brett Hagan, the Company's Senior Vice President, Finance and Chief Accounting Officer, ceased to serve as the Company's principal financial officer, effective as of the Effective Date. Mr. Hagan continues to serve as the Company's principal accounting officer.

Industry Context

The biopharmaceutical industry is highly competitive for executive talent, particularly for experienced financial leaders who can navigate both clinical-stage development and potential commercialization. Kalaris Therapeutics' ability to attract a CFO with a background at both iTeos Therapeutics (clinical-stage) and Sarepta Therapeutics (commercial-stage) indicates a commitment to building a robust leadership team capable of managing complex financial and strategic challenges inherent in the sector. The compensation package offered is consistent with competitive practices in the biotech industry to secure such expertise.

Comparison to Industry Standards

• The base salary of $485,000 and target bonus of 40% are competitive for a CFO at a clinical-stage biopharmaceutical company, aligning with compensation trends for executives with experience from established biotech firms like Sarepta Therapeutics and iTeos Therapeutics.
• The equity grant of 235,000 stock options is a significant incentive, comparable to grants seen in similar-sized biotech companies aiming to attract top-tier talent and align executive interests with long-term shareholder value.
• The severance provisions, particularly the enhanced change-in-control benefits including full equity acceleration, are common in the biotech industry to protect executives during M&A activities, reflecting practices at companies like those Mr. Gall previously served.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for improved financial management and strategic direction from an experienced CFO, but also increased executive compensation costs. The change-in-control severance could impact acquisition value.
• Employees: New leadership in the finance department, potentially impacting departmental structure and operations. Brett Hagan's role adjustment.
• Management Team: Integration of a new key executive into the leadership structure.

Next Steps

• Matthew Gall will commence his duties as Chief Financial Officer and Treasurer on November 3, 2025.
• The Board or compensation committee will conduct annual reviews of Mr. Gall's base salary and bonus eligibility.
• Mr. Gall will be eligible to receive additional equity awards, including in connection with the 2025 year-end compensation review, and at such other times and on such terms and conditions as the Board, or a committee thereof, shall, in its sole discretion, determine.

Key Dates

Recommendation

The appointment of Matthew Gall as CFO is a positive development, bringing significant biopharmaceutical financial and corporate development experience to Kalaris Therapeutics. This strengthens the management team, which is crucial for a clinical-stage company. However, this is a personnel announcement and does not provide new financial results or strategic shifts that would immediately warrant a 'buy' or 'sell' recommendation. The substantial compensation package is a cost consideration, but it is generally in line with industry standards for attracting high-caliber talent. Therefore, a 'hold' recommendation is appropriate as investors should monitor the impact of this new leadership on the company's financial performance and strategic execution over time.

Keywords

Kalaris Therapeutics, CFO appointment, Matthew Gall, biotechnology, pharmaceuticals, executive compensation, corporate governance, SEC filing, 8-K, clinical-stage, financial officer